These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 21517657)

  • 1. Differentiating incretin-based therapies for population-based health care.
    Calabrese D
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
    Wick A; Newlin K
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S5-9. PubMed ID: 20824239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.
    Scheen AJ
    Eur J Intern Med; 2012 Mar; 23(2):126-31. PubMed ID: 22284241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular actions of incretin-based therapies.
    Ussher JR; Drucker DJ
    Circ Res; 2014 May; 114(11):1788-803. PubMed ID: 24855202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Incretin and incretin-based therapies].
    Harada N; Inagaki N
    Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.